Shares of Moderna Inc. (MRNA) gained 1.9% after the biotechnology company said it had received a fast-track designation from the Food and Drug Administration for its COVID-19 vaccine candidate. Moderna has completed the Phase 1 clinical study for the vaccine and has said it is preparing for the mid-stage trial, which will begin "shortly" and is expected to enroll up to 600 participants. There are currently no vaccines that prevent against infections with the novel coronavirus. Moderna's stock has soared 242.0% year-to-date, while the S&P 500 is down 9.3%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
May 12, 2020 08:46 ET (12:46 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.